Trial Profile

Phase I Study of Z-Endoxifen as a Hormonal Therapy for Breast Cancer

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 18 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Endoxifen (Primary)
Indications Advanced breast cancer
Focus Adverse reactions; First in man

Most Recent Events

14 Nov 2024 Planned End Date changed from 30 Oct 2024 to 30 Oct 2025.
17 Sep 2021 Results (n=80) assessing the population pharmacokinetics (PK) of Z-endoxifen in patients with treatment-refractory gynecologic malignancies, desmoid tumors or hormone receptor-positive solid tumors from Mayo Clinic (NCT01327781) and National Cancer Inst (NCI, NCT01273168) trials, presented at the 2021 American College of Clinical Pharmacology Annual Meeting.
30 Aug 2017 Results published in the Journal of Clinical Oncology

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com